← Leaderboards
Anush Oganesian
Tateva Therapeutics, Inc.
$352,000
Attributed
$352,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300K · FY2019–21$500K$375K$250K$125K$0
'19
'20
'21
Funding mix
By agency
NIH$352,000 · 1
By mechanism
R43$352,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Heart Failure”
- Federico Cividini · Cardiac Rsk3 Inhibitors, Llc$10,153,043
- Ionut Bebu · George Washington University$9,972,097
- Barbara Halina Braffett · George Washington University$9,972,097
- Bing Yu · University Of Tx Md Anderson Can Ctr$7,842,501
- Alexander Egbe · Mayo Clinic Rochester$7,415,297
- Daniel Timms · Bivacor, Inc.$7,380,386
Research focus
Heart FailureLegal PatentElementsGenomeInnovationIn VivoEfficacy EvaluationAutologousFibroblastsGenerationsHuman Pluripotent Stem CellCardiacCardiac MyocytesCardiomyopathiesAnimal ModelAdultCellsCell TypeEvaluation StudiesCicatrixBiomaterial CompatibilityGene Expression ProfileHeart InjuriesLink
Grant awards (2)
Direct Reprogramming of Human Fibroblasts into Functional Cardiomyocytes by Non-Integrating Cardiogenic Nanoparticles$52,000
R43 · FY2021 · HL · contact PI
Direct Reprogramming of Human Fibroblasts into Functional Cardiomyocytes by Non-Integrating Cardiogenic Nanoparticles$300,000
R43 · FY2019 · HL · contact PI